Galaxy Surfactants (NSE: GALAXYSURF) Q3 FY26 results signal portfolio resilience as specialty growth offsets global surfactant pressures
Natural Capsules (NSE: NATCAPSUQ) Q3 FY26 results signal operational recovery after regulatory shock, but fermentation execution risk still looms
Read More 6 minute read Pharma Industry News ESSA Pharma shareholders approve XenoTherapeutics acquisition as investors weigh biotech liquidation value ESSA securityholders back XenoTherapeutics acquisition with 99% approval—learn how this deal reshapes biotech exit models and investor sentiment. bySoujanya RaviOctober 7, 2025